This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cempra Inc. Presents Full Data Set Of Phase 2 Clinical Trial Of CEM-101 (Solithromycin) In Community-Acquired Bacterial Pneumonia Patients At The European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)

Stocks in this article: CEMP

CHAPEL HILL, N.C., March 31, 2012 /PRNewswire/ -- Cempra Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections (CABP).  The study also demonstrates solithromycin's favorable safety and tolerability profile compared to levofloxacin.

"This is the first time that the full data set of this Phase 2 trial has been available for review by the infectious disease community," said Prabhavathi Fernandes, chief executive officer of Cempra.  "The promising results of this clinical trial will now be the basis for the initiation of our Phase 3 program in CABP.  We expect to begin the first Phase 3 trial evaluating oral solithromycin in moderate-to-moderately severe CABP patients in the second half of 2012.  Additionally, we are planning Phase 3 trials for 2013 testing the efficacy of intravenous-to-oral step down administration of solithromycin in moderate-to-severe CABP."

CABP is the number one cause of death due to bacterial infection in the U.S. There are over five million cases per year resulting in about one million hospitalizations per year.  Macrolide antibiotics, such as azithromycin (52 million prescriptions in 2010), have been the mainstay of respiratory tract infection treatment but bacterial resistance has been increasing to as high as 30 percent of pneumococcal isolates in the United States.  New antibiotics are needed to confront this rising public health issue.

Oldach et al., ( Abst. # P719; 3:30 to 4:30 p.m. BST, Saturday, March 31) conducted a multi-center, double-blind, randomized Phase 2 clinical trial to evaluate oral solithromycin versus oral levofloxacin in the treatment of adults with moderate to moderately-severe CABP.  One-hundred-thirty-two patients were randomized to receive either solithromycin (800 mg on day one followed by 400 mg on days two to five) or levofloxacin (750 mg on days one through five).  The primary outcome measure was investigator's assessment of clinical success at test-of-cure (TOC; four to 11 days after the last dose of study drug) in the intent-to-treat (ITT) and clinically-evaluable (CE) populations.  Early response to treatment (at day three) was defined as improvement in at least two symptoms (cough, sputum production, chest pain, dyspnea) without worsening in any.

Clinical success rates for solithromycin, compared to levofloxacin, were comparable across endpoints (TOC both ITT and CE, day three ITT and microbiological ITT).  Solithromycin-treated patients experienced fewer treatment-emergent adverse events (29.7%) than levofloxacin-treated patients (45.6%).  No patients on solithromycin discontinued treatment due to an adverse event whereas six patients on levofloxacin discontinued treatment due to an adverse event.  Solithromycin demonstrated efficacy comparable to levofloxacin with a favorable safety and tolerability profile that showed fewer treatment-emergent adverse events than levofloxacin.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs